Radiation Injury, Tumor Sensitization

3 FDA-approved 1 research

HBOT Applications

FDA-Approved Level A

Delayed Radiation Injury

Standard-of-care treatment for osteoradionecrosis and soft tissue radiation necrosis. HBOT promotes angiogenesis in hypoxic, hypovascular, hypocellular irradiated tissue.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 60

Frequency

Once daily, 5×/week

Evidence basis: UHMS / FDA-Approved

References: 9

FDA-Approved Level A

Radiation Cystitis & Proctitis

Approved adjunctive treatment for radiation-induced hemorrhagic cystitis and proctitis, reducing bleeding and promoting mucosal healing.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 40

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 9

Investigational / Preclinical Level C

Tumor Radiosensitization

Investigational use as neoadjuvant therapy to sensitize hypoxic solid tumors to radiotherapy and chemotherapy. Hypoxic tumor microenvironments are resistant to radiation; HBOT may reverse this resistance.

Protocol

Pressure

2.0 – 2.5 ATA

Duration

90 min

Sessions

Per radiation course

Frequency

Prior to each radiation fraction

Evidence basis: Investigational

References: 17

FDA-Approved Level A

Breast Radiation Complications

Effective treatment for late radiation toxicity in breast cancer patients, including radiation dermatitis and tissue necrosis following breast-conserving surgery.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 40

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 9